Related Experiment Video
Updated: Nov 28, 2025
04:53
Author Spotlight: Advances in Evaluating Human Lung Epithelial Cells' Response to Metal-Organic Frameworks
Published on: May 26, 2023
1.5K
Combined Cutaneous Therapy Using Biocompatible Metal-Organic Frameworks
Seyed Dariush Taherzade1,2, Sara Rojas1, Janet Soleimannejad2
1Advanced Porous Materials Unit (APMU), IMDEA Energy, Av. Ramón de la Sagra 3, 28935 Móstoles-Madrid, Spain.
Nanomaterials (Basel, Switzerland)
|December 1, 2020
Summary
New topical patches combine metal-organic frameworks (MOFs) with polyvinyl alcohol (PVA) to deliver antibiotics and anti-inflammatories for skin disorders. These advanced formulations offer enhanced drug loading and controlled release for improved skin treatment.
Area of Science:
- Materials Science
- Nanotechnology
- Dermatology
Background:
- Traditional pharmacological treatments for skin disorders face limitations in efficiency and side effects.
- Metal-organic frameworks (MOFs) present versatile platforms for co-delivering multiple active pharmaceutical ingredients (APIs) due to their porosity, functionalization potential, and biocompatibility.
Purpose of the Study:
- To develop advanced topical patches for combined cutaneous therapy using Fe-carboxylate MOFs (MIL-100 and MIL-127) co-encapsulated with azelaic acid (antibiotic) and nicotinamide (anti-inflammatory) within a polyvinyl alcohol (PVA) matrix.
Main Methods:
- Fabrication of topical patches incorporating MIL-100 and MIL-127 MOFs with PVA.
- Co-encapsulation of azelaic acid (AzA) and nicotinamide (Nic) into the MOF structures.
- Evaluation of drug-loading capacity, release kinetics, and skin permeation of the developed formulations.
Main Results:
- Exceptional drug-loading capacities achieved: 77.4 wt.% (MIL-100) and 48.1 wt.% (MIL-127) for MOF drug content.
- Near-complete drug release (AzA and Nic) within 24 hours, suitable for cutaneous delivery.
- Formulations demonstrated safety, maintained high drug-loading (38.8 wt.% and 24.2 wt.% for MIL-100 and MIL-127, respectively), and enabled controlled skin permeation, with AzA diffusion exceeding commercial standards.
Conclusions:
- Topical PVA-MOF formulations offer a promising platform for advanced cutaneous combined therapy.
- These formulations exhibit high drug-loading capacity and controlled release, improving drug delivery for skin treatments.
- The developed patches represent potential candidates for novel cutaneous devices targeting various skin disorders.
